Biotechnology Graduate Program, School of Science and Engineering, The American University in Cairo, Cairo, Egypt.
Institute of Global Health and Human Ecology, School of Science and Engineering, The American University in Cairo, Cairo, Egypt.
Biomed Res Int. 2020 Nov 24;2020:9593254. doi: 10.1155/2020/9593254. eCollection 2020.
Hepatocellular carcinoma is the fifth most common cancer worldwide and the second most lethal, following lung cancer. Currently applied therapeutic practices rely on surgical resection, chemotherapy and radiotherapy, or a combination thereof. These treatment options are associated with extreme adversities, and risk/benefit ratios do not always work in patients' favor. Anomalies of the epigenome lie at the epicenter of aberrant molecular mechanisms by which the disease develops and progresses. Modulation of these anomalous events poses a promising prospect for alternative treatment options, with an abundance of felicitous results reported in recent years. Herein, the most recent epigenetic modulators in hepatocellular carcinoma are recapitulated on.
肝细胞癌是全球第五大常见癌症,也是第二大致命癌症,仅次于肺癌。目前应用的治疗方法主要依赖于手术切除、化疗、放疗或联合应用。这些治疗方案存在极端的不良反应,风险/获益比并不总是对患者有利。表观基因组的异常处于疾病发展和进展的异常分子机制的中心。这些异常事件的调节为替代治疗方案提供了一个有前途的前景,近年来报道了大量的有益结果。本文综述了肝细胞癌中最新的表观遗传调节剂。